Trials / Completed
CompletedNCT02854605
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-9674 | Tablet administered orally once daily |
| DRUG | Placebo to match GS-9674 | Tablet(s) administered orally once daily |
Timeline
- Start date
- 2016-10-26
- Primary completion
- 2018-01-09
- Completion
- 2018-01-09
- First posted
- 2016-08-03
- Last updated
- 2019-01-29
- Results posted
- 2019-01-29
Locations
37 sites across 6 countries: United States, Canada, Hong Kong, New Zealand, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02854605. Inclusion in this directory is not an endorsement.